Lonza reports CHF 3.03 billion in sales amid divestment of Capsules & Health Ingredients unit

As per the company’s Restated H1 2025 Financials, its continuing business delivered CORE EBITDA of CHF 922 million, representing a margin of 30.4%

AbbVie to acquire Apogee in $10.9 billion immunology power play

Under the agreement, Apogee shareholders will receive $135.11 per share in cash, and the transaction has been unanimously approved by both companies’ boards

Automated cell therapy manufacturing attracts US$1.1 Billion across 34 funding rounds

New Tracxn report highlights growing investor confidence in automated cell therapy production, with Cellares and Ori Biotech dominating funding and regulatory milestones

Orionis expands Novartis partnership in potential $1.4 billion molecular glue drug feal

India’s pharma market to hit US$ 130 billion, exports US$ 80 billion by 2030: ASSOCHAM

Knowledge paper highlights biosimilars, biologics, AI-driven drug discovery and regulatory excellence as key growth drivers for the next phase of India's pharma expansion

GSK bets big on oncology with $10.6 billion Nuvalent acquisition

Deal brings late-stage lung cancer candidates zidesamtinib and neladalkib into GSK’s portfolio

Johnson & Johnson to acquire Firefly Bio in $1 billion oncology push

The acquisition reflects Johnson & Johnson’s push to strengthen its position in antibody engineering and next-generation oncology modalities

Pharma industry poised to reach US$ 130 billion by 2030: Joint Secretary, Department of Commerce

Mohit Yadav reaffirmed government's commitment to improve competitiveness, enhance export capabilities and support the country's transition from volume-driven to value-driven exports

Roche signs up to $2.3 billion deal with Nurix for BTK degrader Bexobrutideg

The agreement underscores Roche’s commitment to advancing innovative therapies for blood cancers and other serious diseases

Servier to acquire Edgewise muscular dystrophy business in $2.65 billion deal

The transaction includes an upfront payment of $1.55 billion, along with up to $1.1 billion in regulatory and commercial milestone payments